** Cannibis-based drugmaker's U.S.-listed shares up11.11 pct at $76.29, snapping a three-day streak of declines
** Company putting together "building blocks" of a researchprogram to see if a cannabis-based medicine could treat symptomsof autism, CEO told The Telegraph (http://bit.ly/1pUWFCw)
** Physicians treating severely epileptic children with theexperimental drug, epidiolex, saw improvements in behavior andbrain function in patients who also had autism, CEO says
** Stock among top percentage gainers on the Nasdaq
** Up to Tuesday's close, the U.S.-listed shares of thecompany had gained 65 pct this year
